Skip to main content
SpringerLink
Log in

Radionuclide Therapy of Lymphomas

Nuclear Oncology

  • 104 Accesses

Abstract

Radioimmunotherapy is an effective therapy for NHL in a variety of settings and is well tolerated. Current studies continue to investigate the role of NHL at various time points in the management of patients with NHL. The limited clinical use of RIT seems to have been driven by economics rather than by a lack of clinical effectiveness. As new radiolabeled agents and indications and nonradioactive agents are being investigated, probably in parallel with nonradioactive agents, close collaborations between medical oncologists and nuclear medicine physicians/radiologists are paramount for optimal integration of these agents into the overall treatment schema for patients with lymphoma.

Radioimmunotherapy (RIT) for treatment of non-Hodgkin lymphoma (NHL) has been undergoing investigations since the early 1990s and became available for clinical use to treat relapsed/refractory NHL in the early 2000s. Since then, the indications for the use of RIT in NHL have been expanded. RIT for NHL is an effective therapy; however, the use in clinical practice has been limited as there are multiple other competing nonradioactive therapies for NHL, several developed in the past few years.

This chapter will provide a review of the current and possible future roles of RIT in patients with lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

[18F]FDG:

2-deoxy-2-[18F]fluoro-D-glucose

AML:

Acute myelogenous leukemia

CR:

Complete response

CHOP:

Chemotherapy regimen based on cyclophosphamide,doxorubicin, vincristine, and prednisone

DLBCL:

Diffuse large B-cell lymphoma

FDA:

United States Food and Drug Administration

Gy:

Gray unit (ionizing radiation dose in the International System of Units, corresponding to the absorption of one joule of radiation energy per kilogram of matter)

HACA:

Human anti-chimeric antibodies

HAMA:

Human anti-mouse antibodies

IPI:

International prognostic index

MDS:

Myelodysplastic syndrome

MTD:

Maximum tolerated dose

NHL:

Non-Hodgkin’s lymphoma

PFS:

Progression-free survival

PR:

Partial response

R:

Rituximab

RIT:

Radioimmunotherapy

SWOG:

Southwest Oncology Group

References

  1. [insert] Zp. Irvine, CA: Spectrum Pharmaceuticals, Inc; 2013.

    Google Scholar 

  2. [insert] Bp. Seattle, WA: GlaxoSmithKline; 2012.

    Google Scholar 

  3. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424–33.

    CAS  PubMed  Google Scholar 

  4. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985;135:973–9.

    CAS  PubMed  Google Scholar 

  5. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, et al. Binding to CD20 by anti-B1 antibody or F(ab’)2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51:15–24.

    Article  CAS  PubMed  Google Scholar 

  6. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678–85.

    CAS  PubMed  Google Scholar 

  7. Brown RS, Kaminski MS, Fisher SJ, Chang AE, Wahl RL. Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. Nucl Med Biol. 1997;24:657–63.

    Article  CAS  PubMed  Google Scholar 

  8. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–66.

    CAS  PubMed  Google Scholar 

  10. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459–65.

    Article  CAS  PubMed  Google Scholar 

  11. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–28.

    Article  CAS  PubMed  Google Scholar 

  12. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18:1316–23.

    Article  CAS  PubMed  Google Scholar 

  13. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–9.

    Article  CAS  PubMed  Google Scholar 

  14. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–63.

    Article  CAS  PubMed  Google Scholar 

  15. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–803.

    Article  CAS  PubMed  Google Scholar 

  16. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10:7792–8.

    Article  CAS  PubMed  Google Scholar 

  17. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25:4285–92.

    Article  CAS  PubMed  Google Scholar 

  18. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma. J Clin Oncol. 2003;21:1263–70.

    Article  CAS  PubMed  Google Scholar 

  19. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–9.

    Article  CAS  PubMed  Google Scholar 

  20. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–64.

    Article  CAS  PubMed  Google Scholar 

  21. Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 2013;31:1977–83.

    Article  CAS  PubMed  Google Scholar 

  22. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009;27:1607–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.

    Article  CAS  PubMed  Google Scholar 

  24. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143–9.

    Article  CAS  PubMed  Google Scholar 

  25. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;3:314–20.

    Article  Google Scholar 

  26. Lopez-Guillermo A, Canales M, Dlouhy I, Briones J, Caballero D, Sancho J, et al. A randomized phase II study comparing consolidation with a single dose of 90Y-Ibritumomab tiuxetan (Zevalin) (Z) vs. maintenance with rituxumab (R) for two years in patients with newly diagnosed follicular lymphoma (FL) responding to R-CHOP. Preliminary results at 36 months from randomization. Blood. 2013;122:P369.

    Google Scholar 

  27. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40:122–35.

    Article  PubMed  Google Scholar 

  28. Wagner Jr HN, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267–72.

    CAS  PubMed  Google Scholar 

  29. Wahl RL. Tositumomab and 131I therapy in non-Hodgkin’s lymphoma. J Nucl Med. 2005;46 Suppl 1:128S–40.

    CAS  PubMed  Google Scholar 

  30. Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res. 2005;11(19 Pt 2):7146s–50.

    Article  CAS  PubMed  Google Scholar 

  31. Vose JM, Bierman PJ, Loberiza Jr FR, Bociek RG, Matso D, Armitage JO. Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin’s lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma. 2007;48:683–90.

    Article  CAS  PubMed  Google Scholar 

  32. Kylstra JW, Huang M, Emmanouilides C, Hagenbeek A, Wiseman G, Von Schilling C, editors. Discriminatory power of the 111-Indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-Yttrium ibritumomab tiuxetan therapeutic regimen: data from 5 trials and 9 years of clinical experience in 45 countries. Annals of oncology. Oxford: Oxford University Press; 2011.

    Google Scholar 

  33. Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P. The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med. 2005;46:1812–8.

    CAS  PubMed  Google Scholar 

  34. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10:1696–711.

    Article  CAS  PubMed  Google Scholar 

  35. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974–81.

    Article  CAS  PubMed  Google Scholar 

  36. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(8 Suppl):14S–20.

    CAS  PubMed  Google Scholar 

  37. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res. 1992;52:637–42.

    CAS  PubMed  Google Scholar 

  38. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008;112(3):830–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, et al. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood. 2009;113:1412–21.

    Article  CAS  PubMed  Google Scholar 

  40. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767–76.

    Article  CAS  PubMed  Google Scholar 

  41. Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin’s lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med. 2007;48:150–7.

    PubMed  PubMed Central  Google Scholar 

  42. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3885–90.

    Article  CAS  PubMed  Google Scholar 

  43. Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006;106:616–22.

    Article  CAS  PubMed  Google Scholar 

  44. Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23:7985–93.

    Article  CAS  PubMed  Google Scholar 

  45. Peyrade F, Italiano A, Fontana X, Peyrottes I, Thyss A. Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment. Lancet Oncol. 2007;8:849–50.

    Article  PubMed  Google Scholar 

  46. Rana TM. Post Bexxar relapse in NHL responds to Zevalin and can be safely accomplished. [Abstract]. Proc Am Soc Clin Oncol. 2003;22:613. #2465.

    Google Scholar 

  47. Tsai DE, Maillard I, Schuster SJ, Nasta SD, Porter DL, Klumpp TR, et al. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin’s lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. Clin Lymphoma. 2003;4:56–9.

    Article  PubMed  Google Scholar 

  48. Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, et al. Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol. 2014;32:212–8.

    Article  CAS  PubMed  Google Scholar 

  49. Witzig TE, Wiseman WG, Geyer SM, et al. A phase I trial of two-sequential doses of ZEVALIN radioimmunotherapy for relapsed low grade B-cell non-Hodgkins lymphoma [Abstract]. Blood. 2003;102:406a. #1475.

    Google Scholar 

  50. Schaefer NG, Huang P, Buchanan JW, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med. 2011;52:830–8.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med. 2010;51:987–94.

    Article  PubMed  Google Scholar 

  52. Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A. Radioimmunotherapy for stem cell transplantation in non-Hodgkin’s lymphoma: in pursuit of a complete response. Oncologist. 2009;14 Suppl 2:41–51.

    Article  CAS  PubMed  Google Scholar 

  53. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangere T, Steinling M, et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:494–504.

    Article  CAS  PubMed  Google Scholar 

  55. Jacene HA, Filice R, Kasecamp W, Wahl RL. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009;50:8–17.

    Article  CAS  PubMed  Google Scholar 

  56. Lopci E, Burnelli R, Ambrosini V, Nanni C, Castellucci P, Biassoni L, et al. 18F-FDG PET in pediatric lymphomas: a comparison with conventional imaging. Cancer Biother Radiopharm. 2008;23:681–90.

    Article  CAS  PubMed  Google Scholar 

  57. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325–9.

    CAS  PubMed  Google Scholar 

  58. Storto G, De Renzo A, Pellegrino T, Perna F, De Falco T, Erra P, et al. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Radiology. 2010;254:245–52.

    Article  PubMed  Google Scholar 

  59. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med. 2000;41:999–1005.

    CAS  PubMed  Google Scholar 

  60. Ulaner GA, Colletti PM, Conti PS. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy – initial experience. Radiology. 2008;246:895–902.

    Article  PubMed  Google Scholar 

  61. Bodet-Milin C, Kraeber-Bodere F, Dupas B, Morschhauser F, Gastinne T, Le Gouill S, et al. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica. 2008;93:390–7.

    Article  PubMed  Google Scholar 

  62. Aviles A, Neri N, Delgado S, Perez F, Nambo MJ, Cleto S, et al. Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. Med Oncol. 2005;22:383–7.

    Article  CAS  PubMed  Google Scholar 

  63. Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol. 2008;36:755–68.

    Article  CAS  PubMed  Google Scholar 

  64. Sharkey RM, Karacay H, Goldenberg DM. Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. Cancer. 2010;116(4 Suppl):1134–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol. 2009;27:3346–53.

    Article  CAS  PubMed  Google Scholar 

  66. Linden O, Hindorf C, Cavallin-Stahl E, Wegener WA, Goldenberg DM, Horne H, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin’s lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005;11:5215–22.

    Article  CAS  PubMed  Google Scholar 

  67. Postema EJ, Raemaekers JM, Oyen WJ, Boerman OC, Mandigers CM, Goldenberg DM, et al. Final results of a phase I radioimmunotherapy trial using 186Re-epratuzumab for the treatment of patients with non-Hodgkin’s lymphoma. Clin Cancer Res. 2003;9(10 Pt 2):3995S–4002.

    CAS  PubMed  Google Scholar 

  68. Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW. 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood. 2009;113:5905–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 2003;101:2340–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine/PET-CT, Department of Imaging, Dana-Farber Cancer Institute and Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA

    Heather A. Jacene & Sree Tirumani

  2. Mallinkrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA

    Richard L. Wahl

Authors
  1. Heather A. Jacene
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sree Tirumani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard L. Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Heather A. Jacene or Richard L. Wahl .

Editor information

Editors and Affiliations

  1. Attending Emeritus, Memorial Sloan-Kettering Cancer Center Dept. Radiology, New York, New York, USA

    H. William Strauss

  2. Professor Emeritus, University of Pisa, Pisa, Italy

    Giuliano Mariani

  3. Associate Professor and Director of Nuclear Medicine, University of Pisa, Pisa, Italy

    Duccio Volterrani

  4. Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Steven M. Larson

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this entry

Cite this entry

Jacene, H.A., Tirumani, S., Wahl, R.L. (2016). Radionuclide Therapy of Lymphomas. In: Strauss, H., Mariani, G., Volterrani, D., Larson, S. (eds) Nuclear Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-26067-9_47-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26067-9_47-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Online ISBN: 978-3-319-26067-9

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Radionuclide Therapy of Lymphomas
    Published:
    25 June 2022

    DOI: https://doi.org/10.1007/978-3-319-26067-9_47-3

  2. Radionuclide Therapy of Lymphomas
    Published:
    04 May 2022

    DOI: https://doi.org/10.1007/978-3-319-26067-9_47-2

  3. Original

    Radionuclide Therapy of Lymphomas
    Published:
    30 December 2016

    DOI: https://doi.org/10.1007/978-3-319-26067-9_47-1

Search

Navigation